Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...

Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action date for FDA decisionGepotidacin could be the first in a new class of oral ...

The Boston Globe reports on findings from researchers at Mass General Brigham who examined "reservoirs" of the covid virus that hide inside people after their acute infections have ended. Also in the ...

Abbott's optimistic forecasts due to high sales of glucose monitors; legal issues with Moderna and GSK; J&J's talc case ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

智通财经APP获悉，葛兰素史克 (GSK.US)周二表示，其呼吸道合胞病毒 (RSV)疫苗在接种后的三个季度都具有保护作用。经季节性因素调整后的数据显示，这种用于老年人的疫苗的三个季度累积有效性为62.9%。

Nodenza Venture Partners launched - focus on international early-stage and pre-commercial ...

UK pharma major GSK has sued USA-based Moderna this week, accusing the latter of violating patents protecting GSK’s COVID-19 ...

London: British drugmaker GlaxoSmithKline (GSK) sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its ...

GSK and CureVac restructured their 2020 collaboration into a new licensing agreement worth up to $1.57 billion in July 2024.

GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...